Literature DB >> 21835525

Newborn screening and maternal diagnosis: rethinking family benefit.

Mara Buchbinder1, Stefan Timmermans.   

Abstract

In a significant departure from established criteria for population screening, a 2006 report by the American College of Medical Geneticists (ACMG) argued that newborn screening may be justified by family and societal benefits even if the screened infant does not stand to benefit. The ACMG report has since been the backdrop for considerable debate about the presumptive benefits of newborn screening. Understandings of family benefits have focused on how information provided by newborn screening may enhance reproductive decision-making, reduce the diagnostic odyssey, and alleviate the burden of raising a child with special health care needs. This paper identifies and describes an additional consequence of newborn screening for families. Specifically, we draw upon audio-recordings and clinical observations from a three-year ethnographic study of expanded newborn screening in California (November 2007-July 2010) to examine the potential for newborn screening to diagnose mothers with genetic disorders. This consequence of expanded newborn screening suggests the possibility of a different type of family spillover from that anticipated by the ACMG report. However, whether this knowledge benefits families depends on how the significance of genetic information is established in the clinic and the family's ability to act on this information. We show that the newborn screening health care infrastructure is not designed to provide treatment for adult patients, so the identification of maternal disease does not necessarily prove beneficial for families.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21835525     DOI: 10.1016/j.socscimed.2011.06.062

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  8 in total

Review 1.  Newborn bloodspot screening policy framework for Australia.

Authors:  Peter O'Leary; Susannah Maxwell
Journal:  Australas Med J       Date:  2015-09-30

Review 2.  International differences in the evaluation of conditions for newborn bloodspot screening: a review of scientific literature and policy documents.

Authors:  Marleen E Jansen; Selina C Metternick-Jones; Karla J Lister
Journal:  Eur J Hum Genet       Date:  2016-11-16       Impact factor: 4.246

3.  Exome/Genome-Wide Testing in Newborn Screening: A Proportionate Path Forward.

Authors:  Vasiliki Rahimzadeh; Jan M Friedman; Guido de Wert; Bartha M Knoppers
Journal:  Front Genet       Date:  2022-07-04       Impact factor: 4.772

4.  Screening criteria: the need to deal with new developments and ethical issues in newborn metabolic screening.

Authors:  John Forman; Fiona Coyle; Jill Levy-Fisch; Pat Roberts; Sharon Terry; Michael Legge
Journal:  J Community Genet       Date:  2012-10-07

5.  Stakeholder attitudes towards the role and application of informed consent for newborn bloodspot screening: a study protocol.

Authors:  S G Nicholls; L Tessier; H Etchegary; J C Brehaut; B K Potter; R Z Hayeems; P Chakraborty; J Marcadier; J Milburn; D Pullman; L Turner; B J Wilson
Journal:  BMJ Open       Date:  2014-11-24       Impact factor: 2.692

6.  Variation among Consent Forms for Clinical Whole Exome Sequencing.

Authors:  Sara A Fowler; Carol J Saunders; Mark A Hoffman
Journal:  J Genet Couns       Date:  2017-07-08       Impact factor: 2.537

Review 7.  Absorbing it all: A meta-ethnography of parents' unfolding experiences of newborn screening.

Authors:  Ashley L White; Felicity Boardman; Abigail McNiven; Louise Locock; Lisa Hinton
Journal:  Soc Sci Med       Date:  2021-09-03       Impact factor: 4.634

8.  Using a social marketing framework to evaluate recruitment of a prospective study of genetic counseling and testing for the deaf community.

Authors:  Yoko Kobayashi; Patrick Boudreault; Karin Hill; Janet S Sinsheimer; Christina G S Palmer
Journal:  BMC Med Res Methodol       Date:  2013-11-25       Impact factor: 4.615

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.